Drug Maker Touts Tests on Bird Flu Vaccine
Drug maker GlaxoSmithKline reported this week that it had achieved good results on an experimental human vaccine for bird flu and said mass production might be possible by 2007.
The company said two shots of its vaccine provoked strong immune responses in more than 80% of people tested. An immune-system booster in the vaccine allows it to use less of the main active ingredient, meaning that greater quantities could be produced if the strain of bird flu known as H5N1 mutated into a form that spread easily among people. The vaccine uses an inactivated version of H5N1 isolated in Indonesia last year.
Start your day right
Sign up for Essential California for news, features and recommendations from the L.A. Times and beyond in your inbox six days a week.
You may occasionally receive promotional content from the Los Angeles Times.
